Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, addresses the use of liquid biopsies in the management of patients with colorectal cancer (CRC) and highlights advantages, for example, the ability to capture tumor heterogeneity using circulating tumor DNA as well as key challenges in the field. Prof. Lenz also discusses the use of liquid biopsies to help consolidate knowledge of tumor mutational burden in CRC and how this can be used to inform treatment approaches using immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).